Company intelligence / Profile preview
Endeavour Cells
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
Overview
Endeavor BioMedicines is a clinical-stage precision medicine company focused on developing therapies for oncology and fibrosis. The company's lead candidate, ENV-101 (taladegib), is a small molecule inhibitor of the Hedgehog signaling pathway currently in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Endeavor is also advancing ENV-501, a next-generation HER3-targeting antibody-drug conjugate (ADC) for the treatment of various solid tumors. By targeting the underlying drivers of disease, Endeavor aims to provide transformative outcomes for patients with high unmet medical needs.
- Therapeutic areas
- OncologyImmunologyPulmonology
- Modalities
- Small moleculeAntibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Endeavour Cells.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endeavour Cells.